Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01576120 · ClinicalTrials.gov registry record · Phase 1
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
A Phase 1 study of Crohn's Disease, sponsored by Medtronic - MITG.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT01576120 is a Phase 1 study of Crohn's Disease that has completed, run by Medtronic - MITG. The registered enrollment target is 40 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01576120, a Phase 1 study of Crohn's Disease, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed study is designed to evaluate Pillcam regimen in Crohn's disease patients, using the PillCam Colon system.
Conditions Studied
Interventions
- OTHER bowel prep regimen first boost 6 oz. and second boost 3 oz.
- OTHER bowel prep regimen first boost 3 oz. and second boost 6 oz.
Study Locations (2)
Georgia
- Atlanta Gastroenterology Associates - Atlanta
Ohio
- Dayton Gastroenterology - Beavercreek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01576120
The ClinicalTrials.gov registry entry for NCT01576120 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (98% lower). The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which bowel prep regimen first boost 6 oz. and second boost 3 oz. is the first listed.
NCT01576120 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT01576120 about?
NCT01576120 is a clinical study titled "Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients". The proposed study is designed to evaluate Pillcam regimen in Crohn's disease patients, using the PillCam Colon system.
What is the current status of trial NCT01576120?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2012-03. Estimated completion is 2014-07.
What conditions does trial NCT01576120 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT01576120?
The interventions under investigation include: bowel prep regimen first boost 6 oz. and second boost 3 oz. (OTHER), bowel prep regimen first boost 3 oz. and second boost 6 oz. (OTHER).
Who is sponsoring clinical trial NCT01576120?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01576120 being conducted?
This trial has 2 study locations across Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Stem Cell Transplantation for Crohn's Disease
RECRUITING · Phase 1
-
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
RECRUITING · Phase 1
-
Beta-Hydroxybutyrate Feasibility Treating IBD
RECRUITING · Phase 1
-
Treatment of Moderate to Severe Refractory Crohn's Disease
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
ACTIVE NOT RECRUITING · Phase 1
-
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.